Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,002,180 papers from all fields of science
Search
Sign In
Create Free Account
dehydroxymethylepoxyquinomicin
Known as:
DHMEQ cpd
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
2 relations
Broader (2)
Benzamides
Cyclohexanones
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Possible role of peritoneal NF-κB in peripheral inflammation and cancer: lessons from the inhibitor DHMEQ.
K. Umezawa
Biomedicine & pharmacotherapy = Biomedecine…
2011
Corpus ID: 30094626
2008
2008
Identification of the RelA domain responsible for action of a new NF-kappaB inhibitor DHMEQ.
Mariko Watanabe
,
M. Nakashima
,
+4 authors
R. Horie
Biochemical and Biophysical Research…
2008
Corpus ID: 35116624
Review
2007
Review
2007
Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.
Alina Katsman
,
K. Umezawa
,
B. Bonavida
Drug resistance updates
2007
Corpus ID: 32592196
Highly Cited
2007
Highly Cited
2007
Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway.
N. Nagai
,
Kanako Izumi-Nagai
,
+8 authors
S. Ishida
Investigative Ophthalmology and Visual Science
2007
Corpus ID: 13064583
PURPOSE To investigate the involvement of the renin-angiotensin system (RAS) and the nuclear factor (NF)-kappaB pathway with…
Expand
Highly Cited
2007
Highly Cited
2007
Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.
A. Jazirehi
,
M. Vega
,
B. Bonavida
Cancer Research
2007
Corpus ID: 17052522
Immunotherapy with rituximab (chimeric anti-CD20 monoclonal antibody, Rituxan), alone or in conjunction with chemotherapy, has…
Expand
Highly Cited
2006
Highly Cited
2006
BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.
I. Palona
,
H. Namba
,
+8 authors
S. Yamashita
Endocrinology
2006
Corpus ID: 25059743
The BRAFV600E mutation is closely linked to tumorigenesis and malignant phenotype of papillary thyroid cancer. Signaling pathways…
Expand
Highly Cited
2005
Highly Cited
2005
Targeting of nuclear factor kappaB Pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo.
G. Matsumoto
,
Jun-ichi Namekawa
,
+5 authors
K. Umezawa
Clinical Cancer Research
2005
Corpus ID: 20615411
We previously designed and synthesized the new nuclear factor kappaB (NF-kappaB) inhibitor dehydroxymethylepoxyquinomicin (DHMEQ…
Expand
Highly Cited
2005
Highly Cited
2005
In vivo antitumor activity of the NF-kappaB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia.
T. Ohsugi
,
R. Horie
,
+6 authors
T. Urano
Carcinogenesis
2005
Corpus ID: 41058364
Adult T-cell leukemia (ATL) is an aggressive neoplasm caused by human T-cell leukemia virus type I (HTLV-I). The nuclear…
Expand
Highly Cited
2004
Highly Cited
2004
Induction of Thyroid Cancer Cell Apoptosis by a Novel Nuclear Factor κB Inhibitor, Dehydroxymethylepoxyquinomicin
D. Starenki
,
H. Namba
,
+4 authors
S. Yamashita
Clinical Cancer Research
2004
Corpus ID: 20748591
Purpose: The objective of the study was to determine the effects of a novel selective nuclear factor κB (NF-κB) inhibitor…
Expand
Highly Cited
2002
Highly Cited
2002
Inhibition of tumor necrosis factor-alpha -induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin.
A. Ariga
,
Jun-ichi Namekawa
,
N. Matsumoto
,
J. Inoue
,
K. Umezawa
Journal of Biological Chemistry
2002
Corpus ID: 25711618
We previously designed and synthesized an NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), that showed anti…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE